Mei Ri Jing Ji Xin Wen·2025-11-07 13:17Core Viewpoint - Fosun Pharma showcases its innovative products and global collaborations at the 8th China International Import Expo, highlighting its deep commitment to the global healthcare sector and continuous breakthroughs [1][3]. Group 1: Product Innovation and Localization - Fosun Pharma has successfully localized several innovative products, including the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, benefiting numerous Chinese patients and enhancing industry standards [3]. - The Yikaida product has treated over 1,000 lymphoma patients since its debut at the first Import Expo in 2018, marking significant advancements in commercial insurance and clinical efficacy [3]. - The Da Vinci surgical robot has been installed over 460 times in mainland China and Hong Kong, serving more than 810,000 patients, with new systems showcased this year expanding its capabilities in minimally invasive surgery [3]. Group 2: Infrastructure and Investment - The launch of the Intuitive Medical headquarters in Shanghai, with an investment of approximately 700 million yuan, marks a significant shift for Fosun Pharma from exhibitor to investor, strengthening its local industrial foundation [4]. - The Magnetic Resonance Guided Focused Ultrasound system has been introduced to over ten key medical institutions in China, treating nearly 1,000 patients, with the new V2 model receiving CE and FDA certifications [4]. Group 3: Strategic Collaborations and Global Operations - Fosun Pharma's Marie® upright particle therapy system, recently FDA approved, represents a new approach to tumor treatment, significantly reducing construction and operational costs while accommodating various advanced therapies [6]. - A strategic partnership with Leo Cancer Care aims to accelerate the introduction of this technology in China, enhancing treatment accessibility for cancer patients [8]. - The company employs a dual strategy of "independent research and development + cooperative introduction," focusing on cutting-edge fields such as antibody therapy, ADC, and gene editing [8]. Group 4: International Expansion and Market Presence - Fosun Pharma's internationalization has progressed beyond trade, entering a new phase of "global operations," with over 1,000 overseas commercialization teams established in markets like the US, Europe, and Southeast Asia [8]. - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for 28.07% of total revenue, indicating strong international market penetration [8]. - The company's self-developed PD-1 inhibitor has been approved in nearly 40 countries, establishing a benchmark for "Chinese innovation going global" [8]. Group 5: Industry Impact and Future Outlook - Fosun Pharma's comprehensive global capabilities are reshaping the international competitiveness of Chinese pharmaceutical companies, serving as a model for industry innovation and integration in an era of global adjustment [9].